 We've come a long way in kidney cancers, just in the last couple of years, not just with understanding the different types, but even within that type, like clear cell medullary papillary, if it's angiogenic for it to be able to be spread or basically pathogenic. So we block the blood vessels because angiogenic uses blood vessels to help grow. Other kidney cell cancers are basically immunogenic, which means their mechanism is escaping the immune system. So if you can re-enable it with immune therapy, you can have success. I sit down with Dr. Pedro Barada, who is an amazing educator and an associate professor at Case Western, as well as the lead genitourinary specialist for medical oncology research at University Hospital's Seidman Center in Cleveland, Ohio. We talk about prostate, bladder, kidney stuff, and it's a very interesting episode and I personally have learned a lot from Pedro. So we hope you check it out on Target Cancer Podcast.